University of Notre Dame DU Lac cut its stake in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) by 28.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,529 shares of the biopharmaceutical company’s stock after selling 14,366 shares during the quarter. University of Notre Dame DU Lac owned 0.07% of Clovis Oncology worth $3,010,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its position in Clovis Oncology by 0.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 20 shares during the last quarter. Hanseatic Management Services Inc. lifted its position in Clovis Oncology by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 13,693 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 37 shares during the last quarter. Aperio Group LLC lifted its position in Clovis Oncology by 1.7% during the second quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 83 shares during the last quarter. Greenwood Capital Associates LLC lifted its position in Clovis Oncology by 4.0% during the second quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 212 shares during the last quarter. Finally, Amalgamated Bank lifted its position in Clovis Oncology by 10.4% during the second quarter. Amalgamated Bank now owns 4,811 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 454 shares during the last quarter.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $84.54, for a total transaction of $253,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 9,000 shares of company stock valued at $653,220 over the last quarter. 12.50% of the stock is currently owned by company insiders.

Shares of Clovis Oncology, Inc. (NASDAQ CLVS) opened at $57.69 on Wednesday. Clovis Oncology, Inc. has a 1-year low of $35.38 and a 1-year high of $99.45. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The firm had revenue of $16.81 million for the quarter, compared to the consensus estimate of $21.12 million. During the same quarter in the prior year, the company earned ($1.70) earnings per share. sell-side analysts forecast that Clovis Oncology, Inc. will post -7.63 EPS for the current fiscal year.

Several equities research analysts have issued reports on the stock. ValuEngine lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday. Leerink Swann restated an “outperform” rating and issued a $90.00 price objective (down from $107.00) on shares of Clovis Oncology in a report on Wednesday, November 15th. Stifel Nicolaus restated a “buy” rating and issued a $125.00 price objective on shares of Clovis Oncology in a report on Friday, November 3rd. Morgan Stanley lowered their price objective on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Finally, Barclays began coverage on shares of Clovis Oncology in a report on Monday, October 23rd. They issued an “overweight” rating and a $105.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $86.15.

COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/06/clovis-oncology-inc-clvs-shares-sold-by-university-of-notre-dame-du-lac.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.